Anika Therapeutics, Inc. ANIK
Medical/Dental Instruments · data as of November 13, 2026
Anika Therapeutics, Inc. (ANIK) is a healthcare company listed in the US with a market value of about $179M. In the twelve months to September 30, 2026 it had revenue of $123M and net income of -$2M, a net margin of -1.4%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 78.2, 5-year revenue growth of -3% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 76% below the current price.
About Anika Therapeutics
Anika Therapeutics is listed in the US and classified in medical/dental instruments. Revenue went from $106M in 2014 to $113M in 2025, growth of about 0.6% a year. It was profitable in 5 of the last 10 years in our data. Its share count fell by 3% over three years (buybacks). It spends 23% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $123M | $113M | $120M | $121M | $114M | $148M | $130M | $115M | $106M | $113M | $103M |
| Net income | -$2M | -$11M | -$56M | -$83M | -$15M | $4M | -$24M | $27M | $19M | $32M | $33M |
| Free cash flow | $2M | $4M | -$2M | -$7M | -$3M | $3M | $11M | $34M | $30M | $32M | $10M |
| EPS (diluted) | $-0.13 | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 | $-1.69 | $1.89 | $1.27 | $2.11 | $2.15 |
| Net margin | -1.4% | -9.6% | -47.0% | -68.4% | -13.1% | 2.8% | -18.4% | 23.7% | 17.7% | 28.1% | 31.5% |
| ROIC | — | -5.1% | -2.2% | 0.3% | 0.6% | 0.7% | -8.1% | 8.3% | 6.7% | 11.9% | 14.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Anika Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 76% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Anika Therapeutics pay a dividend?
Not currently.
Is Anika Therapeutics a good stock to buy?
We do not give buy or sell advice. Anika Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.